80 results about "Somatic antigen" patented technology

The invention discloses an mRNA (messenger ribonucleic acid) transcription skeleton vector and application thereof in preparation of a self-amplification type mRNA vaccine, and belongs to the technical field of veterinary biological products. According to the invention, alphavirus non-structural protein regions NSP2 and NSP3 of a self-amplification type mRNA skeleton are modified, a polyA tail is optimized, and a novel self-amplification type mRNA skeleton is constructed; the self-amplification type mRNA vaccine can improve the antigen expression efficiency, reduce the toxicity of non-structural protein to cells and improve the encapsulation efficiency and delivery efficiency by combining with the optimization of the components and proportion of a lipid nano delivery system, and meanwhile, the self-amplification type mRNA vaccine is wide in applicable pathogen antigen range and can be popularized to more animal epidemic diseases. The characteristics of high-efficiency expression, low-toxicity delivery and single-dose immunization are expected to renovate the immunization strategy of the existing animal vaccine, the epidemic prevention cost of the breeding industry is reduced, and the method has a wide industrial application prospect.

The invention discloses a porcine delta coronavirus spike protein monoclonal antibody, an antigen epitope peptide and application, and belongs to the technical field of biology. The antibody comprises a light chain variable region and a heavy chain variable region, the amino acid sequence of the light chain variable region is as shown in SEQ ID No.1, and the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No.3. According to the invention, a highly conservative linear B cell epitope (the amino acid sequence is DFGEARLD) of a PDCoV spike protein receptor binding domain (S-RBD) and a neutralizing monoclonal antibody capable of being specifically bound to the epitope are identified for the first time. The epitope peptide and the monoclonal antibody provided by the invention can be used for immunological detection and serological investigation of the PDCoV.

The invention relates to the technical field of vaccines, and discloses a preparation method and application of an anti-tumor vaccine based on an autoantigen and a synthetic antigen. The anti-tumor vaccine comprises a tumor autoantigen and a synthetic antigen, wherein the tumor autoantigen is extracted from a tumor cell membrane, a tumor cell lysate, a tumor cell secretion, an exosome antigen or an antigen released by a tumor microenvironment; the synthetic antigen is selected from at least one of a tumor associated antigen, a tumor specific antigen, a personalized neoantigen, a pathogen antigen, a biotoxin, a biomolecule antigen and coding nucleic acid of a peptide type antigen in the antigens; the coding nucleic acid is DNA or mRNA. The vaccine molecule composed of the tumor autoantigen and the synthetic antigen is easy to prepare, has a strong anti-tumor immune effect and good biological safety, solves the problems that the traditional tumor autoantigen has no specific precise target spot and the synthetic antigen is single in immunogen, and has a wide application prospect.

Disclosed in the present invention are a targeted immunotolerance vaccine, a preparation method therefor, and use thereof. The present invention separately modifies a rheumatoid arthritis-related autoantigen peptide and CTLA4 Ig with DSPE-PEG (DP) to prepare a targeted formulation DP-antigen peptide and a targeted formulation DP-CTLA4, which are then mixed to obtain the vaccine. The vaccine described in the present invention, after intravenous injection, binds to albumin in vivo by means of DSPE, "hitchhiking" on albumin to target and enrich in inflammatory lesions, the spleen, the liver, and other tolerance-inducing sites, inhibiting T cell activation, and inducing anergy and apoptosis of rheumatoid arthritis autoantigen-specific T cells, thereby achieving immunotolerance treatment and prevention of rheumatoid arthritis.

This invention provides a kit for detecting anti-peroxidase-1-IgG antibodies, comprising the antigen protein peroxiredoxin-1 (peroxidase-1), a solid-phase carrier, labeled antibody, antigen dilution buffer, sample dilution buffer, antibody dilution buffer, substrate chromogenic agent, washing buffer, standards, positive control, and negative control. This kit utilizes an indirect reaction principle combined with magnetic microparticle chemiluminescence immunoassay to detect anti-peroxidase-1-IgG antibodies in the serum of the test sample. This invention is the first to identify autoantibodies against the target antigen peroxidase-1 in the serum of patients with autoimmune nephrotic syndrome. The provided kit provides a basis for domestic and international research on the molecular mechanisms and clinical diagnosis and treatment of autoimmune nephrotic syndrome related to peroxidase-1 and peroxidase-1-IgG autoantibodies.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

The invention discloses an unknown network threat immunodetector generation method and device, and relates to the technical field of network security, and the method comprises the steps: S1, obtaining a training sample; s2, performing antigen presentation to obtain a training autoantigen set and a training non-autoantigen set; s3, extracting an edge autoantigen; s4, deducing an unknown non-autologous antigen by using the edge autoantigen; s5, carrying out tolerance training on unknown non-autoantigen and autoantigen, adding the antigen subjected to tolerance training as a mature antibody into the t-th generation non-autoantigen set, and generating a network attack detector; s6, judging whether t reaches a preset number of times, and if so, ending; otherwise, entering S7; s7, enabling t + 1 to be equal to t, and returning to S3; according to the method, the autoevolution of the detector is realized, and the immune detector capable of detecting unknown is generated, so that the immune detector can dynamically adapt to an unknown network attack mode; according to the method, an edge benign detector can adaptively optimize and construct an unknown attack process, and unknown network threats can be efficiently and accurately detected.

This disclosure provides an anti-5T4 antigen-binding domain that can be incorporated into antibodies and receptors, including a bispecific anti-5T4 antibody, a biparatopic anti-5T4 antibody, and its antibody-drug conjugate, comprising a first antigen-binding domain that specifically binds to a first 5T4 epitope, a second antibody-antigen-binding domain that specifically binds to a second 5T4 epitope that is not identical to the first 5T4 epitope (the first antigen-binding domain is operably linked to the second antigen-binding domain), and a chemotherapeutic agent. This disclosure further provides methods for using it for the treatment of cancer.

The utility model discloses a mycoplasma detection kit which comprises a kit body, the top end of the kit body penetrates through the bottom end and is provided with a storage cavity, a reinforcing mechanism is inserted into the inner wall of the kit body, the reinforcing mechanism comprises a bottom plate, two fixing mechanisms are fixedly installed at the top end of the bottom plate, the reinforcing mechanism mainly comprises the bottom plate and a plurality of reinforcing rods, and the reinforcing rods are directly inserted into the inner wall of the kit body. According to the kit, the bottom plate can be firmly installed, the rigid strength of the kit body can be improved, the kit body is prevented from deforming, and therefore antivirus function reagents and mycoplasma antigen detection reagents are not prone to being squeezed to be damaged in the transportation and storage process, and the two fixing mechanisms are arranged on the bottom plate; a plastic bottle filled with disinfectant is jointly clamped in the two fixing mechanisms, it can be guaranteed that the plastic bottles of any specification can be effectively fixed through clamping of the fixing mechanisms, and the situation that the plastic bottles are collided and damaged due to transportation shaking is avoided.

The application discloses a kind of nanomaterial and its preparation method and application, the nanomaterial includes exosome and liposome;The exosome expresses immune checkpoint, the exosome is derived from brain glioma cell;The liposome is loaded with I type photosensitizer.The application is by PDT, immune checkpoint and brain glioma cell exosome antigen three tubes simultaneously to remodel tumor local immune microenvironment, greatly improve the efficiency of cancer immunotherapy, can activate strong anti brain glioma immune response and overcome immune escape.

Anti-IGF1R (insulin-like growth factor 1 receptor) antibodies, antigen-binding fragments, and their uses are provided.

Anti-IGF1R (Insulin-like Growth Factor 1 Receptor) antibodies, antigen binding fragments and uses thereof are provided.

The utility model discloses antibody-antigen reaction process display equipment, which comprises an exhibition stand, the exhibition stand comprises a support frame and an interaction table, the interaction table comprises an antibody turntable for representing antibodies and an antigen turntable for representing antigens, and the antibody turntable and the antigen turntable are arranged on the table top of the interaction table. A plurality of antibody tentacles representing different antibody types are arranged on the antibody turntable, and a plurality of antigen tentacles paired with the antibody tentacles are arranged on the antigen turntable; the interaction table further comprises a control system used for controlling the antigen rotating disc and the antibody rotating disc to rotate and enabling the antigen tentacles and the antibody tentacles to be paired. According to the utility model, visitors are enabled to participate in interactive experience through electromechanical interaction, the process of specific binding reaction between antigens and antibodies is intuitively felt and displayed, one antibody can only correspond to one specific antigen, and the knowledge of antigens and antibodies is deepened.

The invention provides a UBC-CK8 / 18 detection kit based on chemiluminescence, and the kit is characterized in that an antibody is immobilized through a streptavidin-biotin system to form a magnetic bead-biotinylated antibody-antigen-acridinium ester labeled antibody compound; after washing, the substrate solution excites the acridinium ester to generate a photon signal, and a relative luminescence unit (RLUs) is captured by a full-automatic chemiluminescence immunoassay instrument, so that rapid and low-cost clinical detection of bladder cancer is realized, and the detection performance is good.

This disclosure relates to anti-BTN3A (Butyrophilin-3A) antibodies, antigen-binding fragments, and the uses thereof.

The present disclosure provides a universal mRNA tumor vaccine and a preparation method and use thereof. The universal mRNA tumor vaccine is constructed based on a concatemer antigen peptide, and comprises a combined peptide segment containing at least two tumor-specific antigen peptides and tumor-associated antigen peptides. The concatemer antigen peptide provided by the present disclosure comprises a plurality of immunogenic antigens. The mRNA tumor vaccine constructed based thereon has good antigen expression efficiency in cells and can produce strong cellular immune effects, and can be used for treating and / or preventing tumors (e.g., colorectal cancer), and can also be combined with other anti-tumor drugs (e.g., anti-PD-1 antibodies) for treating tumors (e.g., colorectal cancer).

The application discloses a mechanism-driven nanobody-antigen binding prediction method and system, relates to the technical field of bio-information processing and artificial intelligence, and inputs amino acid sequences of nanobodies and antigens into a prediction system for processing, and a construction process of the prediction system comprises the following steps: after an encoder encodes the amino acid sequences of the nanobodies and the amino acid sequences of the antigens, global features and local features of respective complementarity determining regions are extracted and fused to obtain nanobody fusion features and antigen fusion features, and the nanobody fusion features and the antigen fusion features are subjected to global average pooling to obtain an encoder feature of the nanobodies and an encoder feature of the antigens; a combination prediction model models the interaction between the encoder feature of the nanobodies and the encoder feature of the antigens through Hadamard product modeling, generates an interaction feature, and predicts a combination probability based on the interaction feature. Through the cooperative work of the mechanism-driven encoder and the prediction system, high-precision and high-efficiency nanobody-antigen binding prediction is realized.

Development of de novo donor specific antibodies (dnDSA) and antibody mediated rejection (AMR) remain to be a barrier for long term graft and patient survival. Most dnDSA are against mismatched donor HLA-DQ antigens. New methods for evaluating HLA-DQ mismatches are provided based on assessment of compositions and locations of categorical amino acid mismatched epitope (CAME). Specifically, amino acid residues of the HLA-DQ protein can be categorized into four groups, and categorical mismatched peptides are ranked in terms of likelihood of presentation by the recipient HLA-DRB1. Applicant has discovered the presence of DQB1 mismatches with %Ranking score ≤1 (corresponding to a binding strength between mismatched DQB1 and DQR1 between donor and recipient being in top 1%) is associated with development of dnDSA in heart transplant recipients, and dnDSA increases the risk of AMR only in recipients who have DQ mismatches with %Ranking score ≤ 1.

This invention discloses a blow-type sampling viral antigen detection kit and its usage method, including a sampler, a blow nozzle, a detection working column, and a equilibration liquid dropper. Sampling is performed by blowing air, a simple sampling method that reduces the probability of sampling errors in untrained individuals. Equilibration liquid is dripped into the funnel-shaped opening of the sampler's receiving tank through the equilibration liquid dropper, continuously eluting the biological sample. The operation is simple and effective. The equilibration liquid, along with the eluted biological sample, enters a colloidal gold filter. The colloidal gold is re-dissolved, captures and labels the viral antigen in the solution. The labeled antigen then enters an antibody filter impregnated with specific antibodies, where it is captured by those antibodies, forming a conjugate of antibody, antigen, and colloidal gold microparticles. A large number of these conjugate microparticles aggregate on the filter membrane above the absorbent cotton column, resulting in color development. The sample elution step is simple, the sampling method is reliable, and the detection and colorimetric observation are easy to perform, making it convenient for the general public to use.

The present disclosure provides nanostructures and nanostructure-based vaccines. Some nanostructures of the present disclosure display antigens capable of eliciting an immune response to infectious agents such as bacteria, viruses, and pathogens. Some vaccines of the present disclosure are useful for preventing or reducing the severity of infection by infectious agents including, but not limited to, Lyme disease, pertussis, herpes virus, orthomyxovirus, paramyxovirus, pneumovirus, filovirus, flavivirus, reovirus, retrovirus, meningococcus, or malaria. The antigens can be attached to the core of the nanostructure non-covalently or covalently, including as a fusion protein or by other means disclosed herein. Multimeric antigens can optionally be displayed along the symmetry axis of the nanostructure. Also provided are proteins and nucleic acid molecules encoding such proteins, vaccine compositions, and methods of administration.

An in vitro expansion process for rapid expansion of antigen specific T cells, such as allogeneic antigen specific T cells comprising the steps culturing in a gas permeable vessel a population of PBMCs (such as allogeneic PBMCs) in the presence of antigen, for example a peptide or peptide mix relevant to a target antigen(s), in the presence of an exogenous cytokine characterized in that the expansion to provide the desired population of T cells is 14 days or less, or example 9, 10, 11 or 12 days, such as 10 days. The disclosure also extends to T cell populations generated by and obtained from the method and the use of same in therapy.

The present disclosure relates to antibodies, antigen binding fragments and methods of use. Specifically, the present disclosure relates to an antibody or an antigen binding fragment thereof that specifically recognizes human hepatobiliary cadherin, and a pharmaceutical use thereof. It is an object of the present disclosure to develop a potential cancer therapy. According to the technical scheme, the invention provides a human-derived anti-liver-intestine cadherin antibody containing a specific amino acid sequence or an antigen binding fragment of the human-derived anti-liver-intestine cadherin antibody. The antibody or the antigen binding fragment thereof has high specificity and affinity to the hepatobiliary cadherin, and can mediate killing of cells expressing the hepatobiliary cadherin. Therefore, the invention also relates to a pharmaceutical composition containing the antibody or the antigen binding fragment thereof, and application of the pharmaceutical composition in preparation of drugs for preventing and / or treating tumors.

The invention belongs to the technical field of analysis and detection, and particularly discloses a capillary electrophoresis fluorescence immunoassay method for detecting abrus precatorius toxin. A fluorescein isothiocyanate (FITC) labeled abrus precatorius toxin antibody probe is prepared, a non-competitive mode is adopted, a sample solution and an FITC labeled antibody are subjected to an incubation reaction, and the FITC labeled antibody is relatively excessive. The FITC labeled antibody-antigen compound and the excessive FITC labeled antibody in the mixed solution are divided into different zones in the separation capillary tube according to different migration rates, and fluorescence signal detection is performed through a window of a laser-induced fluorescence detector in sequence. Qualitative and quantitative analysis is carried out on the abrus precatorius toxin through the fluorescence signal peak and the intensity of the compound. According to the present invention, the detection method of the abrus precatorius toxin fluorescence immunocapillary electrophoresis is clarified, the detection automation is improved while the detection time is reduced compared with the traditional immunization method, the linear range of the abrus precatorius toxin standard solution detection is 75.8-606.4 nM, and the detection limit is 75.8 nM.

To provide reliable positive and negative IHC controls that are highly sensitive, specific, and adaptable to a wide range of targets, including targets for which no suitable biological controls exist.SOLUTION: Synthetic controls include a solid antigen / carrier protein gel comprising purified antigen (e.g., in a known amount) and a carrier protein, such as a serum albumin protein (e.g., a serum albumin protein), an egg white protein or a mixture of egg white proteins, gelatin, or polylysine. In some embodiments, the purified antigen is cross-linked to a carrier protein in a solid antigen / carrier protein gel.SELECTED DRAWING: Figure 3-1

The present disclosure relates to anti-TFR1 (transferrin receptor 1) antibodies, antigen-binding fragments, and uses thereof.

This invention relates to a system and method for assaying the presence of high molecular weight analytes such as proteins, antibodies, antigens, and receptors, using a targeted two-dimensional liquid chromatography-tandem mass spectrometry (2D-LC-MS / MS) system, optionally combined with affinity capture. [Solution] In some embodiments, the system is partially or fully automated. In some embodiments, the system may enable the detection of protein biomarkers (e.g., antibodies or antigens) from clinical or nonclinical biological tissue or fluid samples in the range of pg / mL to ng / mL.

Provided herein are chimeric antigen receptors (CARs) comprising a glucuronoxylomannan receptor antigen-binding domain. Further provided herein are immune cells expressing the GXMR-CARs as well as methods of their use in the treatment of cryptococcosis.

Featured are cells and methods of use thereof for modulating an antigen-specific immune response in a subject. The cells comprise a set of transgenes comprising two or more of PD-L1, HLA-G or H2-M3, Cd47, Cd200, FASG or FasL, Ccl21 or Ccl21b, MfgeS and Serpin B9 or Spi6, that shield the cells from immune surveillance (ie. “cloaking genes”). The cells can be used to induce immune tolerance to an antigen (e.g., a donor alloantigen or a self-antigen), or to induce an immune response to (e.g., induce the production of antibodies directed against) a non-self antigen.

The invention relates to a nanometer antibody and antigen interaction prediction method and device, computer equipment and a storage medium. The method comprises the following steps: obtaining a to-be-detected nano antibody sequence and a to-be-detected antigen sequence; according to the to-be-detected nano-antibody sequence and the to-be-detected antigen sequence, utilizing a first embedding generator to respectively generate a nano-antibody embedding vector and an antigen embedding vector; according to the to-be-detected nano-antibody sequence and the to-be-detected antigen sequence, generating a nano-antibody antigen pair embedding vector by using a second embedding generator; fusing the nano-antibody embedded vector and the nano-antibody antigen pair embedded vector to obtain a nano-antibody fusion feature, and fusing the antigen embedded vector and the nano-antibody antigen pair embedded vector to obtain an antigen fusion feature; and predicting the interaction between the to-be-detected nano-antibody sequence and the to-be-detected antigen sequence according to the nano-antibody fusion characteristics and the antigen fusion characteristics. By adopting the method, the accuracy of predicting the interaction between the nano antibody and the antigen can be improved.

This invention discloses a triple inactivated vaccine containing Mycoplasma gallisepticum, Mycoplasma synoviae, and Infectious Laryngotracheitis in chickens, its preparation method, and its application. The technical solution includes inactivated Mycoplasma gallisepticum antigen, inactivated Mycoplasma synoviae antigen, and inactivated Infectious Laryngotracheitis Virus gD protein; wherein the inactivated Mycoplasma gallisepticum antigen is prepared from Mycoplasma gallisepticum strain YBMG1, and the preservation number of Mycoplasma gallisepticum strain YBMG1 is CCTCC M 20261107. This invention rationally combines Mycoplasma gallisepticum antigen, Mycoplasma synoviae antigen, and chicken infectious laryngotracheitis virus gD protein, and uses saponin as an immune enhancer. This effectively reduces the interference of chicken infectious laryngotracheitis virus gD protein on the immune response of Mycoplasma gallisepticum and Mycoplasma synoviae, and the effect is significantly better than other polysaccharide or polypeptide immune enhancers, thereby achieving simultaneous prevention and control of Mycoplasma gallisepticum disease, Mycoplasma synoviae disease, and chicken infectious laryngotracheitis.